Breaking News

Blue Earth Therapeutics, Seibersdorf Labor Expand Mfg. Pact

Extends existing agreement to include the manufacture of Lutetium (177Lu) rhPSMA-10.1.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Blue Earth Therapeutics Ltd, a Bracco company developing next generation therapeutic radiopharmaceuticals, expanded its manufacturing agreements with Seibersdorf Labor GmbH to include its investigational 225Ac-based radioligand therapy. The agreement provides future supply to UK, EU and U.S. clinical trial sites.    (225Ac) rhPSMA‐10.1, an investigational radiohybrid (rh) Prostate‐Specific Membrane Antigen‐targeted therapeutic radiopharmaceutical, is the second candidate in Blue Earth’s oncolo...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters